Phase 1/2 study of FMC-376 an oral KRAS G12C dual inhibitor in participants with locally advanced unresectable or metastatic solid tumors (PROSPER).

被引：0
|
作者：
Keating, Anne Therese
Papadopoulos, Kyriakos P.
Hloros, Eleni
Spira, Alexander I.
McKean, William Bennion
Krivoshik, Andrew Peter
机构：
[1] Frontier Med, Boston, MA USA
[2] START San Antonio, San Antonio, TX USA
[3] NEXT Oncol Virginia, Fairfax, VA USA
[4] START Mt Region, West Valley City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3184
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations
    Cho, B. C.
    Lu, S.
    Lee, M. A.
    Song, Z.
    Park, J. J. W.
    Lim, S. M.
    Li, Z.
    Zhao, J.
    Richardson, G.
    Zhang, Y.
    Zhang, J.
    Liu, A.
    Chen, C.
    Wang, J.
    Chen, J.
    Wang, A.
    Zhang, J.
    Chen, Z. G.
    Mok, T. S. K.
    Johnson, M. L.
    ANNALS OF ONCOLOGY, 2024, 35 : S493 - S493
  • [2] A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress).
    Ammakkanavar, Natraj Reddy
    Call, Justin
    Shimizu, Toshio
    Kuboki, Yasutoshi
    Liu, Shiyao
    Willard, Melinda D.
    Axelson, Michael
    Heist, Rebecca S.
    Patnaik, Amita
    CANCER RESEARCH, 2022, 82 (12)
  • [3] A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
    Murciano-Goroff, Yonina R.
    Heist, Rebecca S.
    Kuboki, Yasutoshi
    Koyama, Takafumi
    Ammakkanavar, Natraj Reddy
    Hollebecque, Antoine
    Patnaik, Amita
    Shimizu, Toshio
    Spira, Alexander I.
    Nagasaka, Misako
    Han, Ji-Youn
    Iams, Wade Thomas
    Deming, Dustin
    Call, Justin
    Cassier, Philippe
    Han, Sae-Won
    Chu, Quincy Siu-Chung
    Cosman, Rasha
    Durm, Gregory
    Burns, Timothy
    Willard, Melinda D.
    Liu, Shiyao
    Callies, Sophie
    Balar, Arjun V.
    Sabari, Joshua K.
    CANCER RESEARCH, 2023, 83 (08)
  • [4] Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation
    Wang, Judy
    Martin-Romano, Patricia
    Cassier, Philippe
    Johnson, Melissa
    Haura, Eric
    Lenox, Laurie
    Guo, Yue
    Bandyopadhyay, Nibedita
    Russell, Michael
    Shearin, Elizabeth
    Lauring, Josh
    Dahan, Laetitia
    ONCOLOGIST, 2022, 27 (07): : 536 - +
  • [5] A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.
    Li, Jian
    Zhao, Jun
    Cao, Baoshan
    Fang, Jian
    Li, Xiaoyan
    Wang, Mengzhao
    Ba, Yi
    Li, Xingya
    Li, Zhihua
    Liu, Zhe
    Wang, Yongsheng
    Cheng, Ying
    Bai, Chunmei
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors
    Wang, J.
    Zhao, J.
    Zhong, J.
    Li, X.
    Fang, J.
    Yu, Y.
    Li, X.
    Fang, X.
    Chang, J.
    Liu, Z.
    Zhao, Y.
    Song, Q.
    Bai, C.
    Wang-Gillam, A.
    Ding, Y.
    Rao, Z.
    Bi, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S459 - S459
  • [7] Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study
    Zhou, Qing
    Yang, Nong
    Zhao, Mingfang
    Huang, Dingzhi
    Zhao, Jun
    Yu, Yan
    Yuan, Ying
    Sun, Longhua
    Dong, Xiaorong
    Zhang, Tongmei
    Chu, Qian
    Li, Xingya
    Meng, Xiangjiao
    Wang, Huijuan
    Wang, Xiang
    Wu, Dongde
    Hu, Sheng
    Shan, Jinlu
    Liu, Lian
    Sun, Meili
    Zhang, Zhiye
    Zhu, Haibo
    Huang, Jingjing
    Huang, Mengna
    Cheng, Lingge
    Zhang, Sujie
    Zhou, Hui
    Wu, Yi-Long
    EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [8] Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreaK101)
    Fakih, M.
    Durm, G.
    Govindan, R.
    Falchook, G.
    Soman, N.
    Henary, H.
    Hong, D. S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S28
  • [9] First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation
    Heymach, J.
    Kotecki, N.
    Prenen, H.
    Alonso, G.
    Lindsay, C. R.
    Barve, M.
    Thamer, C.
    Eigenbrod-Giese, S.
    Marotti, M. A.
    Van Lancker, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S468 - S468
  • [10] A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors
    Cho, Byoung Chul
    Lu, Shun
    Lee, Myung Ah
    Song, Zhengbo
    Park, John
    Lim, Sun Min
    Li, Ziming
    Zhao, Jun
    Richardson, Gary
    Zhang, Yanqiao
    Zhang, Jun
    Liu, Anwen
    Chen, Cheng
    Wang, Jia
    Lu, Jingtao
    Rui, Haopeng
    Chen, Qian
    Wang, Hui
    Zhang, Jing
    Chen, Zhi Jian
    Mok, Tony
    CANCER RESEARCH, 2024, 84 (07)
12345